https://orcid.org/0000-0002-0912-7011
Figures & data
Table 1. Clinical data of the patients.
Figure 1. Assessment of the left elbow psoriatic lesion treated with MTX microemulsion formulation only along the treatment course for patient 1: (A) before treatment, (B) after 3 weeks of treatment and (C) after 8 weeks of treatment.
Figure 2. Assessment of the right elbow psoriatic lesion treated with MTX microemulsion formulation/fractional erbium:YAG laser along the treatment course for patient 1: (A) before treatment, (B) after 3 weeks of treatment and (C) after 8 weeks of treatment.
Figure 3. Assessment of the left knee psoriatic lesion treated with MTX microemulsion formulation only along the treatment course for patient 2: (A) before treatment, (B) after 3 weeks of treatment and (C) after 8 weeks of treatment.
Figure 4. Assessment of the right knee psoriatic lesion treated with MTX microemulsion formulation/fractional erbium:YAG laser along the treatment course for patient 2: (A) before treatment, (B) after 3 weeks of treatment and (C) after 8 weeks of treatment.
Table 2. TES score of psoriatic plaques before and after 3 and 8 weeks of the treatment.
Figure 5. Patient with psoriatic plaques over the right elbow before treatment with microemulsion/laser combination (A,C) and after 8 weeks of treatment (B,D), showing a decreased epidermal thickness.
Table 3. Comparison between right and left psoriatic plaques regarding the percent change of TES score after 3 and 8 weeks of treatment course.